Novartis | NVS - Loan Capital


Novartis reported $24.24B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Amgen USD 50B 2.43B Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
Bausch Health Companies USD 20.62B 152M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Canopy Growth CAD 226.33M 62.67M Sep/2025
Drreddys Laboratories INR 129.19M 1.84M Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
J&J USD 39.44B 30M Dec/2025
Merck USD 39.97B 6B Sep/2025
Novartis USD 24.24B 174M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Pacira USD 376.72M 1.37M Sep/2025
Perrigo USD 3.61B 7.4M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Phibro Animal Health USD 603.6M 5.92M Dec/2025
Prestige Brands USD 1.05B 39.73M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sanofi EUR 15.72B 150.06M Dec/2025
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Zoetis USD 9.04B 1.97B Dec/2025